Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

Maged A.  El Wakeel; Rania N. Sabry; Ghada M. El-kassas; Shereen A. Abd El-Gaffar; Wael H. El batal; Essam M. Galal; Ashraf Azmy; Eman Awadallah

doi:10.3889/oamjms.2019.638

Authors

Maged A. El Wakeel National Research Centre, Child Health Department, Giza, Egypt
Rania N. Sabry National Research Centre, Child Health Department, Giza, Egypt
Ghada M. El-kassas National Research Centre, Child Health Department, Giza, Egypt
Shereen A. Abd El-Gaffar El-Galaa Maternity Teaching Hospital - Pediatric, Cairo, Egypt
Wael H. El batal National Research Centre, Child Health Department, Giza, Egypt
Essam M. Galal National Research Centre, Child Health Department, Giza, Egypt
Ashraf Azmy National Research Centre, Child Health Department, Giza, Egypt
Eman Awadallah National Research Centre - Clinical and Chemical Pathology, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2019.638

Keywords:

Pentraxin 3, Pulmonary hypertension, Neonates, Congenital heart disease

Abstract

BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long pentraxins, which plays an essential role in regulation of cell proliferation and angiogenesis.

AIM: This study aims to assess serum pentraxin 3 levels in neonates with pulmonary arterial hypertension and compare them in those who have other congenital heart diseases and healthy neonates. Also, we intended to evaluate serum levels of CRP as a mediator of inflammation in the studied groups.

METHODS: The study is a case-control study. Cases were recruited from El Galaa Teaching Hospital, classified into three groups; each group had thirty cases. The first one: cases with pulmonary hypertension (PHT), the second one: cases with congenital heart diseases (CHD) without pulmonary hypertension and the third group included healthy neonates. All participants were subjected to full history taking and full clinical examination. Diagnosis of congenital heart disease and pulmonary hypertension was made according to echocardiographic ï¬ndings by pediatric cardiologist using echocardiography machine. Laboratory investigations included measurement of serum pentraxin 3, Routine CBC, CRP.

RESULTS: This study found that the mean serum pentraxin 3 in PHT neonates was significantly higher than that of the control and CHD neonates (p â‰¤ 0.001, p = 0.02 respectively). Also, the mean Pentraxin3 of the CHD neonates was significantly higher than that of the control (p = 0.06). Also, the mean CRP of the PHT neonates was significantly higher than that of the control (p = 0.01). Regression analysis showed that Pentraxin3 was the main predictor of PAP (P = 0.01).

CONCLUSION: Serum pentraxin 3 is significantly elevated in neonates with pulmonary hypertension, so measurement of pentraxin 3 levels in neonates may be valuable as a predictor for pulmonary hypertension in neonates.